Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model

Journal of Molecular Medicine

Volumn 79, Issue 2, 2001, Pages 133-142

  Nawrath, Michael ^a   Pavlovic, Jovan ^a   Moelling, Karin ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Gp100 tumor associated antigen; Melanoma; Naked DNA; Peptide pulsing; Vaccination

Indexed keywords

DNA VACCINE; EPITOPE; GLYCOPROTEIN GP 100; PLASMID DNA; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; SPLEEN CELL; TUMOR GROWTH;

EID: 0035071065     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000159     Document Type: Article

References (32)

1. Cancer vaccines based on the identification of genes encoding cancer regression antigens
2. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
3. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy
4. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
5. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2. 1 anchor residue
6. The use of melanosomal proteins in the immunotherapy of melanoma
7. A DNA vaccine against malignant melanoma coexpressing antigen and cytokine
8. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17
9. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
10. DNA vaccines
11. DNA immunization targeting the skin: Molecular control of adaptive immunity
12. Genetic vaccination: The advantages of going naked
13. Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC
14. DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity
15. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
16. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
17. Development of a DNA vaccine against malignant melanoma
18. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12 V)
19. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1. 5: Similarity of L3T4 to the human Leu-3/T4 molecule
20. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement
21. Protection against influenza A virus by DNA vaccination depends on the humoral response and dose of challenge virus
22. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
23. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
24. On the role of antigen in maintaining cytotoxic T-cell memory
25. On T cell memory: Arguments for antigen dependence
26. Gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
27. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100
28. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients
29. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
30. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
31. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
32. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants